Comments
AstraZeneca Pharma India on Wednesday launched an anti-diabetic tablet ‘Xigduo XR’ used for the treatment of type 2 diabetes in adults. The drug is a product of AstraZeneca group and is approved in 61 countries, including the US, the EU and Japan, AstraZeneca said. It is a combination of metformin and dapagliflozin, an inhibitor of sodium-glucose cotransporter 2, it added. Xigduo XR is available in multiple dosage strengths. Investors will closely watch the development.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.